DANAHER CORP

Danaher Corporation (NYSE: DHR) is a global science and technology innovator committed to accelerating the power of science and technology to improve human health. The company operates through three primary segments: Biotechnology, Life Sciences, and Diagnostics, each serving distinct but complementary markets within the life sciences and healthcare industries.

The Biotechnology segment, established through the 2015 acquisition of Pall and expanded via the 2020 acquisition of Cytiva, provides equipment, consumables, software and services for advancing biotherapeutic research, development, and manufacturing. The Life Sciences segment encompasses instruments, consumables, services and software for studying DNA, RNA, proteins, metabolites and cells, along with filtration and purification products. This segment was established in 2005 through the acquisition of Leica Microsystems and has grown through subsequent acquisitions including Beckman Coulter, Phenomenex, IDT, Aldevron, and Abcam. The Diagnostics segment offers clinical instruments, consumables, software and services used by hospitals and laboratories for disease diagnosis and treatment decisions, established in 2004 through the acquisition of Radiometer and expanded through acquisitions including Cepheid and HemoCue.

Danaher operates approximately 60,000 employees across roughly 50 countries, with significant presence in North America, Western Europe, and high-growth markets. The company's geographic sales mix reflects North America at 41 percent of total revenue, with the remainder distributed across developed and high-growth international markets. The company markets products under key brands including Cytiva, Pall, Abcam, Aldevron, Beckman Coulter, Cepheid, HemoCue, Leica Microsystems, Molecular Devices, Phenomenex, and Sciex.

The company's operations are unified by the Danaher Business System, a comprehensive management philosophy emphasizing continuous improvement, innovation, and customer focus. Danaher's business model emphasizes recurring revenue through direct sales channels and strategic acquisitions that provide access to specialized technologies and domain expertise. The company generates revenue through both recurring product sales and consumables, as well as nonrecurring equipment and services. Danaher's competitive advantages derive from its portfolio of market-leading brands, integrated technology platforms, global distribution capabilities, and commitment to research and development across its served markets.